Early bcr-abl transcript levels predict future molecular response
More patients in the nilotinib arm vs the imatinib arm achieved BCR-ABL transcript levels ≤1% (56% vs 16%) and ≤10% (91% vs 67%) at 3 months. Early molecular response at 3 months correlated with future MMR and MR4.5 as well as an increased probability of freedom from progression and OS. Citation: A Hochhaus et al. … Read more